Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target?
Cui, Huanhuan L.
Wong, Kum Thong
KAUST DepartmentBiological and Environmental Sciences and Engineering (BESE) Division
Computer, Electrical and Mathematical Sciences and Engineering (CEMSE) Division
Online Publication Date2018-02-06
Print Publication Date2018-12
Permanent link to this recordhttp://hdl.handle.net/10754/627076
MetadataShow full item record
AbstractBackgroundGlioblastoma (GBM) is the most common malignant brain tumor with median survival of 12-15 months. Owing to uncertainty in clinical outcome, additional prognostic marker(s) apart from existing markers are needed. Since overexpression of endothelin B receptor (ETBR) has been demonstrated in gliomas, we aimed to test whether ETBR is a useful prognostic marker in GBM and examine if the clinically available endothelin receptor antagonists (ERA) could be useful in the disease treatment.MethodsData from The Cancer Genome Atlas and the Gene Expression Omnibus database were analyzed to assess ETBR expression. For survival analysis, glioblastoma samples from 25 Swedish patients were immunostained for ETBR, and the findings were correlated with clinical history. The druggability of ETBR was assessed by protein-protein interaction network analysis. ERAs were analyzed for toxicity in in vitro assays with GBM and breast cancer cells.ResultsBy bioinformatics analysis, ETBR was found to be upregulated in glioblastoma patients, and its expression levels were correlated with reduced survival. ETBR interacts with key proteins involved in cancer pathogenesis, suggesting it as a druggable target. In vitro viability assays showed that ERAs may hold promise to treat glioblastoma and breast cancer.ConclusionsETBR is overexpressed in glioblastoma and other cancers and may be a prognostic marker in glioblastoma. ERAs may be useful for treating cancer patients.
CitationVasaikar S, Tsipras G, Landázuri N, Costa H, Wilhelmi V, et al. (2018) Overexpression of endothelin B receptor in glioblastoma: a prognostic marker and therapeutic target? BMC Cancer 18. Available: http://dx.doi.org/10.1186/s12885-018-4012-7.
SponsorsThis work was supported by Sten A Olssons Foundation for Research and Culture, Family Erling-Persson Foundation, Torsten Söderberg Foundation, BILTEMA Foundation, lngaBritt and Arne Lundbergs Foundation, Stichting af Jochnick Foundation, Jane and Dan Olssons Research Foundation, Nexttobe, Swedish Cancer Foundation, Children’s Cancer Foundation, Swedish Medical Research Council, Thematic Cardiovascular Research Center and Stockholm County Council, and the Swedish Heart-Lung Foundation, VINNOVA-BIO-X and Medivir AB (all to CSN), Cure cancer /Bota Cancer (to KCY). The funding body had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.
RelationsIs Supplemented By:
Except where otherwise noted, this item's license is described as This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Endothelin B receptor expression in malignant gliomas: the perivascular immune escape mechanism of gliomas.
- Authors: Nakashima S, Sugita Y, Miyoshi H, Arakawa F, Muta H, Ishibashi Y, Niino D, Ohshima K, Terasaki M, Nakamura Y, Morioka M
- Issue date: 2016 Mar
- Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
- Authors: Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, Meling T, Murrell W, Vik Mo EO, Langmoen IA
- Issue date: 2015 Sep 22
- A 63 signature genes prediction system is effective for glioblastoma prognosis.
- Authors: Zhang Y, Xu J, Zhu X
- Issue date: 2018 Apr
- Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells.
- Authors: Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, Dong Q, Soto H, Choe J, Dembo A, Wheeler H, Eskin A, Schmid I, Yong WH, Mischel PS, Cloughesy TF, Kornblum HI, Nelson SF, Liau LM, Tso CL
- Issue date: 2011 Dec
- Gene and microRNA Signatures Are Associated with the Development and Survival of Glioblastoma Patients.
- Authors: Yang Q, Wang R, Wei B, Peng C, Wang L, Hu G, Kong D, Du C
- Issue date: 2019 Jul